

Part I Cancer Prevention and Health Politics

1	Do We Make Optimal Use of the Potential of Cancer Prevention?	3
	Peter Greenwald and Barbara K. Dunn	
1.1	Introduction	4
1.2	Lifestyle Interventions	4
1.3	Medical Interventions	7
1.4	The Changing Landscape of Clinical Studies	7
1.5	Prevention Clinical Trials	9
1.6	Biomarkers for Cancer Prevention	11
1.7	Systems Biology	13
1.8	Future Directions for Attaining Optimal Impact in Cancer Prevention	14
	References	15
2	Predictors of Successful Cancer Prevention Programs	19
	Franz Porzsolt, Anita Kirner, and Robert M. Kaplan	
2.1	Introduction	19
2.2	Methods	20
2.3	Results	20
2.3.1	Quality of Prevention Programs	20
2.3.2	Recommended Prevention Programs	24
2.3.3	Critical Appraisal of Traditional Selection Criteria	25
2.3.4	Incidence in Primary and Secondary Prevention	26
2.4	Discussion	27
	References	29

3	Cancer Prevention in the Developing World: Mission Impossible?	33
	Franco Cavalli	
3.1	A Changing Pattern.....	33
3.2	A Possible Roadmap	35
3.3	A Provisional Conclusion	37
	References.....	38
4	Is Cancer Prevention Ever Going to Be Profitable?	41
	Thomas D. Szucs and Konstantin J. Dedes	
4.1	Introduction.....	41
4.2	What Will Be the Economic Future of Cancer Care?	42
4.3	How Do We Determine "Value for Money"?.....	42
4.3.1	Types of Formal Economic Evaluations.....	45
4.3.2	Applying Cost-Effectiveness Evaluations.....	46
4.4	So Will Cancer Prevention Ever Be Profitable?	46
	References.....	47
 Part II Cancer Prevention: The Scientific-Epidemiological Base		
5	Energy Metabolism, Cancer Risk, and Cancer Prevention	51
	Michael Pollak	
	References	53
6	Promises and Limitations of Biomarkers	55
	David F. Ransohoff	
6.1	Promise Versus Product.....	55
6.2	Threats to Validity from Chance and Bias	55
6.3	Addressing Current Problems.....	56
6.3.1	Every Study Should Be Reliable.....	56
6.3.2	Drug Research Versus Marker Research.....	56
6.3.3	Role of Specimens	57
6.3.4	Shortcuts: By Using Already-Collected Specimens	57
6.4	Conclusion	58
	References.....	58
 Part III Cancer Prevention, Tobacco and Nutrition		
7	The EPIC Study: An Update	63
	Paolo Vineis and Elio Riboli	
7.1	The EPIC Study Design	63
7.1.2	Exposure Variables.....	64
7.1.3	Follow-Up and Case Ascertainment.....	64
7.1.4	Biological Samples	65

7.2	Recent Find ings on Diet and Biomarkers	65
7.2.1	Fibres, Meat Intake and Colorectal Cancer.....	65
7.2.2	Cancer, Hormones and BMI	65
	References.....	68
8	Anti-angiogenic Properties of Chemopreventive Drugs:	
	Fenretinide as a Prototype	71
	Ilaria Sogno, Roberta Venè, Cristina Sapienza, Nicoletta Ferrari, Francesca Tosetti, and Adriana Albini	
8.1	Molecular Regulators of Angiogenesis as Drug Targets for Chemoprevention.....	71
8.2	Angioprevention: When Cancer Chemoprevention Meets Angiogenesis	72
8.3	Retinoids and 4HPR as Angiopreventive Molecules	73
	References.....	74
9	Retinoids and Breast Cancer Prevention	77
	Bernardo Bonanni and Matteo Lazzeroni	
9.1	Introduction.....	77
9.2	Clinical Trials.....	78
9.3	Fenretinide and Ovarian Cancer	80
9.4	Conclusions and Future Perspectives.....	80
	References.....	81
Part IV Cancer Prevention, Genetics and Vaccines		
10	Cancer Prevention by Vaccination Against Hepatitis B	85
	Mei-Hwei Chang	
10.1	Introduction.....	85
10.2	Cancer Prevention by Vaccination	86
10.2.1	Advantage of Cancer Prevention by Vaccination.....	86
10.3	Chronic Hepatitis B Virus Infection and Hepatocellular Carcinoma	87
10.4	Strategies to Prevent Viral Hepatitis B-Associated Hepatocellular Carcinoma	87
10.4.1	Primary Prevention by Immunoprophylaxis	87
10.4.2	Treatment of Viral Hepatitis/Cirrhosis.....	87
10.4.3	Chemoprevention	87
10.4.4	Liver Transplantation for End-Stage Cirrhosis	88
10.5	Cancer Prevention by Hepatitis B Vaccination	88
10.6	Why Should the Hepatitis B Vaccine Be Given at Birth to Prevent Cancer?	88
10.7	Hepatitis B Immunoprophylaxis Program	89
10.8	Impact of Universal Hepatitis B Immunization on Chronic Infection	90

10.9	Demonstration of the Efficacy of Cancer Prevention by Hepatitis B Vaccination.....	90
10.10	Problems in Preventing Liver Cancer by Vaccination.....	90
10.10.1	Inadequate Resources	91
10.10.2	Ignorance or Poor Compliance Due to Anxiety to the Safety of Vaccine	91
10.10.3	Vaccine Failure or Nonresponders	91
10.10.4	No Effective Vaccine Available	92
10.11	Conclusions and Future Prospects	92
10.11.1	Hepatoma Control.....	92
10.11.2	Implication to the Control of Other Cancers	92
	References.....	92

Part V Cancer Prevention and Target Organs I: Breast Cancer

11	Energy Restriction for Breast Cancer Prevention.....	97
	Anthony Howell, Mary Chapman, and Michelle Harvie	
11.1	Introduction.....	97
11.2	Risk Factors for Breast Cancer	98
11.3	Effect of Weight and Weight Gain and Exercise Deficiency on Breast Cancer Risk.....	98
11.4	Mechanism of Weight Gain and Exercise Deficiency on Risk.....	99
11.5	Chronic Energy Restriction Reduces Cancer Risk	99
11.6	Intermittent Energy Restriction Also Reduces Breast Cancer Risk	100
11.7	Mechanism of the Effect of CER and IER	100
11.8	Energy Restriction Mimetic Agents.....	101
11.9	Inhibitors of Glycolysis.....	102
11.10	Inhibitors of Lipid Synthesis	103
11.11	Activation of AMP-Activated Protein Kinase.....	104
11.12	Stimulation of Mitochondrial Activity and Fat Oxidation	104
11.13	Activation of SIRT1	104
	Summary and Conclusions	105
	References.....	105
12	The Use of Tamoxifen and Raloxifene for the Prevention of Breast Cancer	113
	D. Lawrence Wickerham, Joseph P. Costantino, Victor G. Vogel, Walter M. Cronin, Reena S. Cecchini, Leslie G. Ford, and Norman Wolmark	
12.1	Introduction.....	114
12.2	The Study of Tamoxifen and Raloxifene	114
12.3	Results.....	115
12.3.1	Invasive Breast Cancer.....	115

12.3.2	Noninvasive Breast Cancer	116
12.3.3	Other Secondary Endpoints	116
12.4	Discussion	117
	References	118
13	Prevention of ER-Negative Breast Cancer	121
	Yuxin Li and Powel H. Brown	
13.1	SERMs and Aromatase Inhibitors	122
13.2	Novel Agents for the Prevention of ER-Negative Breast Cancer	123
13.3	Retinoids	124
13.4	Vitamin D Receptor	127
13.5	EGFR/Tyrosine Kinase Inhibitors	127
13.6	COX-2 Inhibitors	129
13.7	Statins	130
13.8	Combination Chemoprevention	130
13.9	Conclusion	131
	Acknowledgement	131
	References	132
14	Exogenous and Endogenous Hormones, Mammographic Density and Breast Cancer Risk: Can Mammographic Density Be Considered an Intermediate Marker of Risk?	135
	Susen Becker and Rudolf Kaaks	
14.1	Introduction	135
14.2	General Determinants and Correlates of Mammographic Density	137
14.3	Sex Steroid Hormones and Breast Density	137
14.3.1	Postmenopausal Hormone Replacement Therapy	137
14.3.2	Endogenous Sex Hormones	138
14.4	Selective Estrogen Receptor Modulators	142
14.5	Aromatase Inhibitors	143
14.6	Gonadotropin-Releasing Hormone Agonists	144
14.7	IGF-I and Its Binding Proteins	145
14.8	Prolactin	146
14.9	Discussion	149
	References	150
Part VI	Cancer Prevention and Target Organs II: Cancer of the Digestive Tract	
15	Chemoprevention of Oesophageal Cancer and the AsPect Trial	161
	Debashish Das, Andrew P. Chilton, and Janusz A. Jankowski	
15.1	Introduction	161
15.2	Barrett's Oesophagus	162

15.3	Need for Chemoprevention Approach Rather Than Surveillance	162
15.4	The AsPECT Trial	163
15.5	Trials Related to AsPECT	164
15.6	The Evidence Base for Using Aspirin and Esomeprazole	165
15.6.1	Aspirin	165
15.6.2	Esomeprazole.....	165
15.7	Conclusion	167
	References.....	167

Part VII Cancer Prevention and Target Organs III: Prostate Cancer

16	Review of Diagnostic Markers for Prostate Cancer	173
	Fritz H. Schröder	
16.1	Characteristics of PSA-Driven Screening.....	174
16.1.1	PSA and Cancer Aggressiveness	175
16.2	How to Improve on PSA in the Detection of Prostate Cancer?	176
16.2.1	PSA Use in Men Less Than 50 Years Old.....	176
16.3	Selective Detection of Aggressive Prostate Cancer	178
16.3.1	PSA Velocity	179
16.4	Needs and Expected Future Developments	179
16.5	Conclusions.....	180
	References.....	180
17	Selenium and Vitamin E Cancer Prevention Trial: A Nutrient Approach to Prostate Cancer Prevention	183
	Barbara K. Dunn, Anne Ryan, and Leslie G. Ford	
17.1	Introduction.....	183
17.1.1	A Preventive Approach to the Problem of Prostate Cancer	183
17.1.2	SELECT: Selection of Study Interventions	184
17.2	SELECT: Study Design	186
17.2.1	Study Objectives	186
17.2.2	Selection of Study Agents.....	186
17.2.3	Study Cohort.....	187
17.2.4	Study Design.....	187
17.2.5	Statistical Considerations.....	188
17.2.6	Evaluation of Prostate Cancer Endpoint.....	189
17.2.7	SELECT in Contrast to PCPT	189
17.2.8	Ancillary Studies	189
17.3	Study Implementation.....	190
17.4	Future Challenges in the Conduct of SELECT.....	190
	References.....	191

18	Prostate Cancer Prevention by Short-Term Anti-androgens: The Rationale Behind Design of Pilot Studies	195
	Tim Oliver, Attila Lorincz, and Jack Cuzick	
18.1	Introduction.....	195
18.2	Modern Evidence of a Contributory Role for Sexually Acquired Infection to Causation of Prostate Cancer But Lack of Specificity of Organism.....	196
18.3	Modern Ideas on the Role of Inflammation as Causative of Malignant Transformation and Its Relevance to Prostate Cancer	197
18.4	PSA Screening and Impact on Over-Diagnosis of Prostate Cancer	198
18.5	Evidence of Harm from Prostate Biopsy	199
18.6	Lack of Evidence of Major Therapeutic Gain from Current Approaches to Radical Treatment of Prostate Cancer	199
18.7	Possible New Approaches to Chemo-prevention of Prostate Cancer	200
18.8	Choice of Patient Populations for Chemo-prevention Studies.....	200
18.8.1	Patients with Low-Grade Prostate Cancer Volunteering for Surveillance Protocols.....	200
18.8.2	Patients with Persistent PSA Elevation After a Negative Biopsy Developing Prostate Cancer	201
18.8.3	Patients with STDs.....	201
18.8.4	Patients with Male Factor Infertility	201
18.9	Conclusion	202
	References.....	202

Part VIII Cancer Prevention: Metabolic Aspects

19	Anti-angiogenic Activity of a Novel Class of Chemopreventive Compounds: Oleanic Acid Terpenoids	209
	Ilaria Sogno, Nicola Vannini, Girecia Lorusso, Rosaria Cammarota, Douglas M. Noonan, Luca Generoso, Michael B. Sporn, and Adriana Albini	
19.1	Introduction.....	210
19.2	Angioprevention and Anti-angiogenic Therapy	210
19.3	Triterpenoids: New Promising Angiogenesis Regulators	211
	References.....	212

**Part IX Aspirin and NSAIDs in Cancer Prevention:
Attempts at an International Consensus**

20	Pharmacologic Effects of NSAIDs and Implications for the Risks and Benefits of Long-Term Prophylactic Use of Aspirin to Prevent Cancer	215
	Michael J. Thun and Bonny Blackard	
20.1	Introduction.....	215
20.2	Risk–Benefit Considerations	219
20.3	Conclusions.....	220
	References.....	220
21	Aspirin and NSAIDs for the Prevention of Colorectal Cancer	223
	John A. Baron	
21.1	Introduction.....	223
21.2	Colorectal Neoplasia: Observational Studies	224
21.3	Clinical Trial Data: Sporadic Colorectal Neoplasia.....	225
21.4	Special Populations.....	226
	References.....	227
22	Aspirin and Cancer Risk: A Summary Review to 2007	231
	Cristina Bosetti, Silvano Gallus, and Carlo La Vecchia	
22.1	Introduction.....	231
22.2	Materials and Methods	231
22.3	Results.....	232
22.3.1	Colon and Rectal Cancer	232
22.3.2	Other Digestive Tract Cancers	238
22.3.3	Lung Cancer.....	243
22.3.4	Breast and Ovarian Cancers.....	243
22.3.5	Prostate Cancer	244
22.3.6	Bladder and Kidney Cancers	244
22.3.7	Lymphatic and Haematopoietic Cancers	244
22.4	Discussion.....	245
	References.....	245